+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Huntington Disease - Pipeline Review, H2 2019

  • ID: 4894144
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 345 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Active Biotech AB
  • ArunA Biomedical Inc
  • F. Hoffmann-La Roche Ltd
  • NeuroNascent Inc
  • Primary Peptides Inc
  • SOM Biotech SL
  • MORE
Huntington Disease - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease - Pipeline Review, H2 2019, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.

Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Huntington Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 10, 13, 57, 16 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 3 molecules, respectively.

Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Active Biotech AB
  • ArunA Biomedical Inc
  • F. Hoffmann-La Roche Ltd
  • NeuroNascent Inc
  • Primary Peptides Inc
  • SOM Biotech SL
  • MORE
Introduction
Huntington Disease - Overview
Huntington Disease - Therapeutics Development
Huntington Disease - Therapeutics Assessment
Huntington Disease - Companies Involved in Therapeutics Development
Huntington Disease - Drug Profiles
Huntington Disease - Dormant Projects
Huntington Disease - Discontinued Products
Huntington Disease - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Huntington Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Huntington Disease - Pipeline by Active Biotech AB, H2 2019
Huntington Disease - Dormant Projects, H2 2019
Huntington Disease - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Huntington Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Active Biotech AB
  • AcuraStem Inc
  • Addex Therapeutics Ltd
  • Adeptio Pharmaceuticals Ltd
  • AFFiRiS AG
  • Alkermes Plc
  • Allianz Pharmascience Ltd
  • Alsonex Pty Ltd
  • Anima Biotech Inc
  • Annexon Inc
  • Armgo Pharma Inc
  • ArunA Biomedical Inc
  • Asklepios BioPharmaceutical Inc
  • Avergen Pharmaceuticals GmbH
  • Azevan Pharmaceuticals Inc
  • BrainStorm Cell Therapeutics Inc
  • Brainvectis SAS
  • BridgeBio Pharma Inc
  • Celon Pharma SA
  • Chaperone Therapeutics Inc
  • Chong Kun Dang Pharmaceutical Corp
  • Cleave Therapeutics Inc
  • Collaborative Medicinal Development LLC
  • Curyx Bio Inc
  • DanPET AB
  • Dystrogen Therapeutics SA
  • Emerald Health Sciences Inc
  • Evotec SE
  • Exicure Inc
  • F. Hoffmann-La Roche Ltd
  • Genervon Biopharmaceuticals LLC
  • Hope Biosciences LLC
  • Immungenetics AG
  • Krisani Bio Sciences Pvt Ltd
  • Living Cell Technologies Ltd
  • Locana Inc
  • Medesis Pharma SA
  • MindImmune Therapeutics Inc
  • Mitochon Pharmaceuticals Inc
  • Mitoconix Bio Ltd
  • Mitokinin LLC
  • MMJ International Holdings Corp
  • Navitor Pharmaceuticals Inc
  • NeuBase Therapeutics Inc
  • NeuExcell Therapeutics Inc
  • Neurimmune Holding AG
  • Neurodon LLC
  • NeuroNascent Inc
  • New World Laboratories Inc
  • NLS Pharma Group
  • Novartis AG
  • Nuredis Inc
  • Omeros Corp
  • Ophidion Inc
  • Oryzon Genomics SA
  • Oscine Therapeutics
  • Oxalys Pharmaceuticals Inc
  • PharmatrophiX Inc
  • Priavoid GmbH
  • Primary Peptides Inc
  • ProQR Therapeutics NV
  • Prous Institute for Biomedical Research SA
  • PTC Therapeutics Inc
  • reMYND NV
  • Resilio Therapeutics LLC
  • Retrotope Inc
  • Sage Therapeutics Inc
  • Secura Bio Inc
  • Seneb BioSciences Inc
  • Shinkei Therapeutics LLC
  • SOM Biotech SL
  • Sosei Heptares
  • Spark Therapeutics Inc
  • Stealth BioTherapeutics Corp
  • T3D Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • Thelial Technologies SA
  • TreeFrog Therapeutics SAS
  • Ultragenyx Pharmaceutical Inc
  • UniQure NV
  • Vaccinex Inc
  • Vitality Biopharma Inc
  • Vivoryon Therapeutics AG
  • Voyager Therapeutics Inc
  • Vybion Inc
  • Wave Life Sciences Ltd
Note: Product cover images may vary from those shown
Adroll
adroll